Corcept Therapeutics Incorporated (CORT)

Net profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	106,140	91,386	94,616	94,500	101,418	116,870	112,733	111,844	112,512	106,453	97,607	99,411	106,011	109,398	114,113	105,972	94,181	86,808	78,215	76,225
Revenue (ttm)	US$ in thousands	482,375	450,026	428,153	413,824	401,858	397,624	392,027	380,229	365,978	352,891	343,087	340,064	353,874	356,034	351,212	334,904	306,486	285,422	268,362	258,417
Net profit margin		22.00%	20.31%	22.10%	22.84%	25.24%	29.39%	28.76%	29.41%	30.74%	30.17%	28.45%	29.23%	29.96%	30.73%	32.49%	31.64%	30.73%	30.41%	29.15%	29.50%

December 31, 2023 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $106,140K ÷ $482,375K
= 22.00%

Corcept Therapeutics Inc has maintained a relatively stable net profit margin over the past eight quarters, ranging from 20.31% to 29.41%. The net profit margin indicates the percentage of revenue that translates into profit after accounting for all expenses. The company's net profit margin peaked at 29.41% in Q1 2022 and has been gradually decreasing since then, with the latest figure at 22.00% in Q4 2023. This downward trend may be a cause for further analysis to assess the company's operational efficiency and cost management strategies. Overall, Corcept Therapeutics Inc has demonstrated consistent profitability, although the recent decline in net profit margin warrants careful monitoring to ensure sustainable financial performance.